Evaluation of the relative severity of pulmonary neutrophilic inflammation and therapeutic modification with intravenous prolastin by means of 18 fluoro-2-deoxyglucose (18FDG) positron emission tomography (PET)/computerised tomography (CT) scanning in subjects with usual chronic obstructive pulmonary disease (COPD) and alpha 1-antitrypsin deficiency

niversity Hospitals Birmingham NHS Foundation Trust (UK)0 个研究点目标入组 30 人开始时间: 2008年10月31日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•Healthy controls:
•1. Healthy subjects
•2. Both males and females, aged 50 - 70 years
•3. Those who have never smoked regularly for more than 3 months
•4. No evidence of lung disease
•5. Forced expiratory volume in 1 second (FEV1) greater than 75% predicted, FEV1/forced vital capacity (FVC) greater than 70% predicted
•6. No relevant medical or mental disorder
•7. Able to give informed consent
•COPD patients:
•1. Emphysema with no other active lung disease
•2. FEV1 less than 75% predicted, FEV1/FVC less than 70% predicted, carbon monoxide transfer coefficient (KCO) less than 80% predicted (or known emphysema on previous CT scan)
•3. Fewer than two acute exacerbations in the previous 12 months and no recent exacerbations (within 2 months)
•4. No other relvant medical or mental disorder
•5. Able to give informed consent
•Patients with alpha 1-antitrypsin deficiency:
•1. PiZ phenotype
•2. Emphysema with no other active lung disease
•3. FEV1 less than 75% predicted, FEV1/FVC less than 70% predicted, KCO less than 80% predicted (or known emphysema on previous CT scan)
•4. Fewer than two acute exacerbations in the previous 12 months and no recent exacerbations (within 2 months)
•5. No other relvant medical or mental disorder
•6. Able to give informed consent

发起方

niversity Hospitals Birmingham NHS Foundation Trust (UK)